3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
15
Leukemia, Myeloid, Chronic-Phase
6
Neoplasm Metastasis
4
Neoplasms
3
Philadelphia Chromosome
2
Ovarian Neoplasms
2
Myeloproliferative Disorders
2
Leukemia
2
Synovitis, Pigmented Villonodular
1
Sarcoma
1
Recurrence
1
Peritoneal Neoplasms
1
Neoplasm, Residual
1
Melanoma
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Giant Cell Tumor of Tendon Sheath
1
Genital Neoplasms, Female
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Chordoma
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Blast Crisis
1
Appendiceal Neoplasms
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Cyclophosphamide
51
fludarabine
37
Dexamethasone
35
venetoclax
30
pembrolizumab
25
Rituximab
20
pomalidomide
18
Lenalidomide
17
Gemcitabine
17
fludarabine phosphate
15
Etoposide
14
Cytarabine
13
daratumumab
12
carfilzomib
11
Temozolomide
11
Injections
10
Calcium Dobesilate
10
glofitamab
9
Nivolumab
9
Cisplatin
9
Bortezomib
9
Azacitidine
9
selinexor
8
Vincristine
8
Immunotherapy, Adoptive
8
obinutuzumab
7
cemiplimab
7
Drug Therapy
7
Carboplatin
7
zanubrutinib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
nilotinib
×
1 year
×
Clear all
NCT01774630
2026-05-26
NiloPost-STIM
University Hospital, Bordeaux
Phase 2
Completed
31 enrolled